Peptides for Weight Loss: Which Ones Have Real Human Trial Data?

Evidence tiers: every weight-loss peptide compared

The table below is the fastest way to see where each molecule actually sits. Percentages are mean changes from baseline in the trial's primary analysis, not what any individual should expect.

What are peptides for weight loss?

A peptide is a short chain of amino acids — long enough to act like a hormone, short enough to be manufactured synthetically. The peptides that matter for body weight are copies or modifications of hormones your gut, pancreas and pituitary already release to tell the brain how much fuel is on board.

Glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), amylin, glucagon and ghrelin all proved to be tractable drug targets, and mapping how they regulate hunger and energy use produced today's obesity drugs (PMID 34067710). GLP-1 slows gastric emptying, boosts glucose-dependent insulin release and curbs appetite via hypothalamic and brainstem receptors — the GLP-1 receptor (GLP-1R) (PMID 17928588). Newer drugs add agonism at the GIP receptor (GIPR), the glucagon receptor (GCGR) or the amylin receptor to push the effect further.

Native GLP-1 is useless as a drug — DPP-4 enzymes destroy it within minutes. Modern agonists add fatty-acid chains and amino-acid swaps that resist degradation and bind albumin, stretching the half-life enough for weekly dosing (PMID 31050435). Almost all are injected because gut enzymes break peptides down before they cross the intestinal wall (PMID 15984901).

That distinction matters commercially. "Peptide" is not a category of efficacy — it is a category of chemistry. Wegovy and a vial of AOD9604 from an overseas website are both peptides. Only one of them has a phase 3 outcome dataset behind it. Our explainer on GLP-1 receptor agonists covers the mechanism in more depth.

Do peptides for weight loss actually work?

Some do, dramatically. Most of the ones marketed online do not.

The honest version of the answer splits into three groups. First, peptides that have completed randomized, placebo-controlled phase 3 trials with body weight as the primary endpoint and are approved by regulators — semaglutide, tirzepatide, liraglutide. Second, peptides in active late-stage development whose published phase 2 results are strong but whose approval and long-term safety are unresolved — retatrutide, cagrilintide combinations. Third, everything else: molecules with an interesting mechanism, an animal study, and a supplement industry built on top of them.

The size of the gap between group one and group three is easy to underrate. Obesity pharmacology has an unusually long graveyard of compounds that looked promising in rodents and either failed in humans or were withdrawn for safety (PMID 23092275). Mechanistic plausibility has repeatedly failed to predict clinical results in this field, which is exactly why "it increases lipolysis in adipocytes" is not evidence that a peptide will make a person lose weight.

Tier 1: approved drugs with phase 3 data

Semaglutide

STEP 1 randomized 1,961 adults with overweight or obesity to weekly semaglutide 2.4 mg or placebo alongside lifestyle intervention (NCT03548935). At week 68 the semaglutide group had lost a mean 14.9% of body weight — about 15.3 kg — versus 2.4% (2.6 kg) on placebo. Responder rates tell the same story: 86.4% reached at least 5% loss, 69.1% at least 10% and 50.5% at least 15%, against 31.5%, 12.0% and 4.9% on placebo (PMID 33567185). That result is the reference point every newer molecule is measured against. Full detail sits in our semaglutide research summary.

Bottom line: the reference-standard GLP-1 drug — about 15% mean loss over 68 weeks in STEP 1, with roughly half of patients losing 15% or more; FDA-approved as Wegovy; prescription-only.

Tirzepatide

Tirzepatide adds GIP receptor agonism to GLP-1. In SURMOUNT-1, 2,539 adults without diabetes received weekly tirzepatide at 5, 10 or 15 mg or placebo for 72 weeks (NCT04184622); mean weight reductions were 15.0%, 19.5% and 20.9% against 3.1% for placebo. Between 85% and 91% of tirzepatide participants reached at least 5% loss versus 35% on placebo, and 57% on the 15 mg dose reached at least 20% loss versus 3% on placebo (PMID 35658024). In people who also had type 2 diabetes — historically a harder population to move — SURMOUNT-2 still produced 12.8% and 14.7% reductions (PMID 37385275). The head-to-head trial SURMOUNT-5 (NCT05822830) compared the two directly and found 20.2% loss with tirzepatide versus 13.7% with semaglutide at 72 weeks (PMID 40353578). See tirzepatide and the tirzepatide vs semaglutide comparison.

Bottom line: the most effective approved obesity drug to date — up to about 21% mean loss in SURMOUNT-1 and superior to semaglutide head-to-head in SURMOUNT-5; FDA-approved as Zepbound; prescription-only.

Liraglutide

The oldest of the three and the weakest performer. The SCALE trial found a mean 8.0% weight reduction at 56 weeks with daily liraglutide 3.0 mg versus 2.6% on placebo (PMID 26132939). Critical reviews have noted the modest effect size relative to cost and the daily injection burden (PMID 28392927). It is still clinically useful, but it explains why weekly agents took the market. Head-to-head comparisons across the class are reviewed in PMID 33767808. More in our liraglutide page.

Bottom line: the oldest and weakest of the approved GLP-1 drugs — about 8% mean loss over 56 weeks in SCALE and a daily rather than weekly injection; FDA-approved as Saxenda; prescription-only.

Tier 2: investigational peptides still in trials

Retatrutide

Retatrutide hits three receptors — GIP, GLP-1 and glucagon — with the glucagon arm intended to raise energy expenditure rather than only suppress intake. Its phase 2 obesity trial reported a mean 24.2% weight reduction at 48 weeks at the highest dose studied, against 2.1% for placebo (PMID 37366315). Parallel phase 2 work in type 2 diabetes (PMID 37385280) and in metabolic dysfunction-associated steatotic liver disease (PMID 38858523) showed large reductions in liver fat.

Two caveats get lost when those numbers circulate on social media. Phase 2 results routinely shrink in phase 3, and retatrutide is not approved by any regulator — which means the vials being sold online under that name are unapproved copies of an unlicensed investigational drug of unverified content. Our retatrutide summary handles the trial data in full.

Bottom line: the largest weight-loss signal of any obesity peptide so far — about 24% mean loss at 48 weeks in a phase 2 trial — but investigational only, now in phase 3 (the TRIUMPH program) and not approved by any regulator.

Cagrilintide and CagriSema

Cagrilintide is a long-acting amylin analogue. Amylin is co-secreted with insulin and contributes a satiety signal that operates partly independently of GLP-1, so combining the two is an attempt at additive appetite suppression. In REDEFINE 1 (NCT05567796), weekly coadministered cagrilintide and semaglutide produced a mean 20.4% weight reduction at 68 weeks versus 3.0% on placebo (PMID 40544433). Still not approved. See cagrilintide.

Bottom line: an amylin-plus-GLP-1 combination with roughly 20% mean loss in the phase 3 REDEFINE program; completed pivotal trials but investigational and not yet approved anywhere.

Tier 3: sold for fat loss, thin human evidence

AOD9604 and HGH fragment 176-191

AOD9604 is a synthetic fragment of the C-terminal region of human growth hormone, designed to keep the lipolytic activity of GH without the effects on blood glucose or IGF-1. Chemically it is Tyr-hGH(177-191) — the hGH 177-191 sequence with an added tyrosine — commonly marketed as "hGH fragment 176-191," so the two names refer to the same lineage of molecule. The foundational work showed reduced body weight and increased fat oxidation in obese mice (PMID 11713213). It reached human obesity trials in the 2000s and was never approved for obesity in any jurisdiction — the program did not produce a marketable efficacy result. It is now sold as a research chemical and as an unapproved cosmetic or supplement ingredient. Read the detail on AOD9604.

Bottom line: persuasive fat-loss data exists only in rodents; human obesity trials never yielded a marketable result and it is approved for weight loss nowhere — a marketing story, not a treatment.

MOTS-c

MOTS-c is a peptide encoded in mitochondrial DNA with genuinely interesting biology in metabolic regulation and exercise response (PMID 36761202). Human data is observational: plasma MOTS-c concentrations correlated with insulin sensitivity in lean but not obese individuals (PMID 29593067). A correlation in lean people is not a fat-loss treatment. No randomized trial has tested administered MOTS-c for weight loss in humans. See MOTS-c.

Bottom line: genuinely interesting metabolic biology, but human evidence is observational only and no controlled trial has shown administered MOTS-c causes weight loss; a research compound, not a treatment.

Tesamorelin

Tesamorelin is the strongest case of a peptide whose evidence is real but routinely misrepresented. It is a growth hormone-releasing hormone analogue approved specifically to reduce excess abdominal fat in HIV-associated lipodystrophy. In its registration trials it reduced visceral adipose tissue by roughly 15% over 26 weeks without a meaningful change in total body weight (PMID 20554713), and a later study confirmed reductions in visceral and liver fat in the same population (PMID 25038357). Selective fat redistribution in one clinical population is not general obesity treatment. Details on our tesamorelin page.

Bottom line: real, approved evidence — but only for reducing visceral fat in HIV-associated lipodystrophy, with little change in total body weight; never approved for general weight loss.

Lipotropic blends and everything else

Compounded "lipo" injections generally contain methionine, inositol, choline and B vitamins, sometimes with a peptide added for marketing weight. There is no adequately powered randomized evidence that these produce clinically meaningful weight loss. The same applies to the repair and recovery peptides frequently upsold alongside fat-loss protocols — reviews of BPC-157 note that human clinical evidence remains scarce and that unregulated product quality is a distinct hazard from the molecule itself (PMID 40789979).

Bottom line: no adequately powered randomized evidence that lipotropic or fat-burner peptide blends produce meaningful weight loss; the peptide on the label is doing marketing work, not clinical work.

Failed and withdrawn obesity drugs

The reason to be sceptical of any new fat-loss molecule is written into the history of the field. Several obesity drugs cleared trials, reached the market and were then pulled when harms emerged — a pattern that explains why regulators now demand cardiovascular outcome data and why a rodent study is not a green light. The FDA, the European Medicines Agency (EMA) and national bodies such as the UK's MHRA and Australia's TGA have each forced withdrawals in this class.

The common thread is that mechanism and short-term weight loss were never the problem — the problem was the safety signal that only long, large trials revealed. That is exactly the kind of evidence today's grey-market peptides do not have, which is why plausible biology should never be mistaken for a proven, tolerable treatment.

Timeline: how the drug class arrived

Incretin-based weight-loss drugs did not appear overnight. The approval and milestone chain runs from the first GLP-1 agonists for diabetes to today's multi-receptor agents:

• 2005 — exenatide (Byetta), the first GLP-1 receptor agonist approved, for type 2 diabetes. See exenatide.
• 2014 — liraglutide 3.0 mg (Saxenda, Novo Nordisk), the first GLP-1 agonist approved specifically for weight management.
• 2017 / 2021 — semaglutide (Ozempic for diabetes in 2017; Wegovy for weight management in 2021, Novo Nordisk), validated by the STEP program.
• 2022 / 2023 — tirzepatide (Mounjaro for diabetes in 2022; Zepbound for weight management in 2023, Eli Lilly), the first GIP/GLP-1 dual agonist, validated by the SURMOUNT program.
• 2023 — retatrutide reports phase 2 obesity results as a GIP/GLP-1/glucagon triple agonist (Eli Lilly).
• 2025 — CagriSema (cagrilintide plus semaglutide, Novo Nordisk) reports phase 3 REDEFINE results; not yet approved.

Longer-acting diabetes relatives such as dulaglutide (Trulicity) sit alongside this line. The direction of travel is consistent: each generation stacks more hormone receptors to push efficacy higher.

Pipeline: what is coming next

The obesity pipeline is unusually crowded, and the direction is toward oral dosing and additional hormone targets. Everything below is investigational — none of it is approved for weight loss, and vials sold online under these names are unlicensed copies of unproven drugs.

• Orforglipron (Eli Lilly) — an oral small-molecule GLP-1 receptor agonist. Because it is a small molecule rather than a peptide, it need not be injected; it is in late-stage clinical development.
• Survodutide (Boehringer Ingelheim / Zealand Pharma) — a GLP-1/glucagon dual receptor agonist in clinical development for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
• Mazdutide (Eli Lilly / Innovent) — a GLP-1/glucagon dual agonist in clinical development, studied primarily in China.
• Amycretin (Novo Nordisk) — an amylin and GLP-1 receptor co-agonist in early-to-mid-stage clinical development, explored in both injectable and oral forms.
• CagriSema (Novo Nordisk) — cagrilintide plus semaglutide; completed the phase 3 REDEFINE program but not yet approved.
• Retatrutide (Eli Lilly) — the GIP/GLP-1/glucagon triple agonist, now in phase 3 (the TRIUMPH program) after strong phase 2 results.

Phase 2 numbers routinely shrink in phase 3, and late-stage safety can still end a program, as the withdrawn drugs above show. Until a regulator approves one of these, its real-world efficacy and safety in the general population remain unproven.

Who is eligible for weight-loss peptides?

Trial and label eligibility for the approved drugs is narrower than the online conversation suggests. What follows is an educational summary of who the studies enrolled and who the labels cover — not a recommendation that any individual should start treatment.

A separate, much rarer category is genetic obesity. Setmelanotide (Imcivree) is a melanocortin-4 receptor agonist approved for specific rare genetic obesity syndromes rather than common obesity — a reminder that "weight-loss peptide" spans very different clinical situations, and that eligibility is always a clinician's judgement, not a self-assessment.

Benefits beyond weight loss

The newer GLP-1 based drugs increasingly earn approvals for outcomes other than the number on the scale, which is part of why clinicians treat them as metabolic medicines rather than cosmetic ones.

The landmark result is the SELECT cardiovascular outcomes trial (NCT03574597). Among 17,604 adults with overweight or obesity (BMI ≥ 27) and established cardiovascular disease but without diabetes, weekly semaglutide cut the primary composite of cardiovascular death, non-fatal heart attack or non-fatal stroke by about 20% — reaching 6.5% of the semaglutide group versus 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72–0.90) (PMID 37952131). It was the first weight-loss drug to demonstrate a cardiovascular outcome benefit, and it reshaped how the FDA, the EMA and health-technology bodies such as the UK's NICE position the class.

Beyond the heart, the class has picked up further approved indications. Tirzepatide is approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, and semaglutide has an approval in metabolic dysfunction-associated steatohepatitis (MASH). These are regulator-approved uses in defined populations, not blanket claims — but they show the benefits extend past weight itself.

How they compare: surgery and lifestyle

Weight-loss peptides vs bariatric surgery

Two comparisons help calibrate expectations. The first is against bariatric surgery, still the most effective obesity treatment by magnitude of weight loss.

Neither is presented here as the better option — that is a clinical decision that depends on the individual. The point is that the newest drugs narrowed, but did not close, the gap with surgery.

Drug plus lifestyle vs lifestyle alone

The second comparison is built into the trials. Every phase 3 study gave both arms the same reduced-calorie diet and activity programme, so the placebo arm shows what lifestyle change alone achieved and the difference is the drug effect.

Across the class, lifestyle alone produced roughly 2–3% mean loss over a year or more, while adding the drug multiplied that several-fold. It also underlines that these drugs were tested alongside diet and activity, not instead of them.

What do weight-loss peptides cost?

Pricing is one of the most volatile parts of this topic, so treat every figure here as a rough range, not a quote.

List price is not what most insured patients pay: manufacturer savings programs, national health systems and negotiated formularies all move the real number, in either direction. Because prices and coverage change frequently, confirm current figures with a pharmacist or prescriber rather than a web page.

How fast do weight-loss peptides work?

Faster than most people expect on appetite, slower than most people expect on the scale. Participants in the GLP-1 trials generally noticed reduced hunger and earlier fullness within the first few weeks of starting, but the weight-loss curves in STEP 1 and SURMOUNT-1 did not flatten until well past the one-year mark. STEP 1 ran 68 weeks; SURMOUNT-1 ran 72. Dose escalation is deliberately slow to limit nausea, so early weeks are spent below the dose that produced the headline result.

The other half of the timing question is what happens when treatment stops. In the STEP 1 extension, participants who came off semaglutide regained roughly two thirds of the weight they had lost within a year, and the improvements in blood pressure, lipids and glycemic markers moved back toward baseline (PMID 35441470). This is the most important single fact about the class and the one least represented in marketing.

Side effects reported in the trials

Gastrointestinal effects dominate every trial in this class, are usually mild to moderate, and are worst during dose escalation. The frequency picture from the phase 3 trials:

Unapproved peptides carry a different risk profile entirely, because the risk is unquantified. The instructive precedent is melanotan-2, a peptide sold online for years before case reports linked unregulated use to melanoma diagnoses, rhabdomyolysis and other harms (PMID 28266027). Absence of reported side effects for a research chemical usually reflects absence of surveillance, not safety.

Who should not use weight-loss peptides?

The approved GLP-1 based drugs carry specific contraindications and cautions. This is a scannable summary of label warnings, not personal medical advice — a clinician screens for these before prescribing.

Are weight-loss peptides legal?

Every peptide with credible weight-loss evidence is a prescription-only medicine in the United States, United Kingdom, European Union and Australia. There is no legal consumer channel for them outside a prescription. Retatrutide and cagrilintide are not approved anywhere, which places them outside even that channel.

The grey market works around this with labeling. Vials marked "research use only" or "not for human consumption" are sold without any of the identity, purity, sterility or dose-accuracy controls applied to a licensed medicine. The FDA has separately warned about unapproved and compounded GLP-1 products, including dosing errors and products using salt forms such as semaglutide sodium that are not the ingredient studied in the trials. Several research peptides — including MOTS-c and BPC-157 — have been placed in Category 2 of the FDA's interim 503A bulk substances list, meaning the agency identified significant safety risks for use in compounding. Our guide to peptide legality breaks the rules down by country.

What is worth tracking if you are prescribed one

If a clinician has put you on one of the approved drugs, the variables that actually inform the next appointment are unglamorous: the date of each weekly injection, which site was used, the titration step you are on and when it changed, side effects and their timing relative to the dose, weight trend over months rather than days, and food and activity patterns as appetite shifts. Titration decisions are clinical calls made on that history — which means the history has to exist and be accurate.

Most people try to hold this in memory or a notes app and lose the thread by month three, which is exactly when the data becomes useful. A structured log is the difference between "I think the nausea was worse after the increase" and a dated record your prescriber can read in ten seconds. Our guide on how to track peptides and medications covers the mechanics.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity — PubMed 33567185
2. Tirzepatide Once Weekly for the Treatment of Obesity — PubMed 35658024
3. Tirzepatide once weekly for obesity in people with type 2 diabetes — PubMed 37385275
4. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — PubMed 40353578
5. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — PubMed 26132939
6. Liraglutide for weight management: a critical review of the evidence — PubMed 28392927
7. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — PubMed 37366315
8. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes — PubMed 37385280
9. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease — PubMed 38858523
10. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — PubMed 40544433
11. Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
12. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — PubMed 37952131
13. GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
14. The physiology of glucagon-like peptide 1 — PubMed 17928588
15. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMed 31050435
16. The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710
17. Oral delivery of peptide drugs: barriers and developments — PubMed 15984901
18. Obesity pharmacotherapy: current perspectives and future directions — PubMed 23092275
19. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism — PubMed 11713213
20. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation — PubMed 20554713
21. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients — PubMed 25038357
22. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — PubMed 36761202
23. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not obese individuals — PubMed 29593067
24. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues — PubMed 28266027
25. Regeneration or Risk? A Narrative Review of BPC-157 — PubMed 40789979
26. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials — PubMed 18022033
27. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects (SCOUT) — PubMed 20818901
28. Cancer Risk Associated with Lorcaserin — The FDA's Review of the CAMELLIA-TIMI 61 Trial — PubMed 32905671
29. Valvular heart disease associated with fenfluramine-phentermine — PubMed 9271479

Primary sources — trial registrations and drug reference records for the landmark studies and approved drugs:

• STEP 1 (semaglutide) — ClinicalTrials.gov NCT03548935
• SURMOUNT-1 (tirzepatide) — ClinicalTrials.gov NCT04184622
• SURMOUNT-5 (tirzepatide vs semaglutide) — ClinicalTrials.gov NCT05822830
• SELECT (semaglutide cardiovascular outcomes) — ClinicalTrials.gov NCT03574597
• REDEFINE 1 (CagriSema) — ClinicalTrials.gov NCT05567796
• Drug reference records: semaglutide, tirzepatide, liraglutide, retatrutide and tesamorelin.

Keep reading